Publicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (77)

2024

  1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

    Cancers, Vol. 16, Núm. 9

  2. Concordancia entre las escalas de valoración del riesgo de tromboembolismo venoso en pacientes con patología médica en urgencias

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 36, Núm. 5, pp. 342-350

  3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  4. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  5. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  2. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  3. Impacto del manejo en urgencias en la evolución de los pacientes con trombosis venosa superficial aislada de miembros inferiores: subanálisis del estudio ALTAMIRA

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 2, pp. 109-116

  4. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  5. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  3. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism

    Cancers, Vol. 14, Núm. 17

  4. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  5. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  2. Characteristics of isolated superficial vein thrombosis and diagnostic-therapeutic management in spanish hospital emergency departments:The altamira study

    Emergencias, Vol. 33, Núm. 6, pp. 433-440

  3. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  4. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome

    Frontiers in Immunology, Vol. 12

  5. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370